Greg Harrison
Stock Analyst at B of A Securities
(4.54)
# 272
Out of 5,005 analysts
101
Total ratings
64.94%
Success rate
17.22%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $454.93 | +1.77% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $37.85 | +13.61% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $26.22 | +18.23% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $10.94 | +82.82% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $54.10 | +5.36% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $402.70 | +8.77% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $455.65 | -1.24% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $40.60 | +60.10% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.17 | +26.38% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $2.40 | +359.29% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $20.95 | +67.06% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $30.76 | +78.80% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $22.70 | +63.00% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $15.79 | +64.66% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $24.35 | -17.86% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.29 | +16.73% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $26.40 | +51.52% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $69.02 | +8.66% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.60 | +32.35% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $20.72 | +339.19% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $26.58 | -54.85% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.68 | +119.56% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $3.89 | +285.60% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $4.49 | -33.18% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.66 | +4,107.74% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.08 | +198.67% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $59.80 | +50.50% | 5 | Mar 14, 2022 |
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $454.93
Upside: +1.77%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $37.85
Upside: +13.61%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $26.22
Upside: +18.23%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $10.94
Upside: +82.82%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $54.10
Upside: +5.36%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $402.70
Upside: +8.77%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $455.65
Upside: -1.24%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $40.60
Upside: +60.10%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.17
Upside: +26.38%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $2.40
Upside: +359.29%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $20.95
Upside: +67.06%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $30.76
Upside: +78.80%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $22.70
Upside: +63.00%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $15.79
Upside: +64.66%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $24.35
Upside: -17.86%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.29
Upside: +16.73%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $26.40
Upside: +51.52%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $69.02
Upside: +8.66%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.60
Upside: +32.35%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $20.72
Upside: +339.19%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $26.58
Upside: -54.85%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.68
Upside: +119.56%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $3.89
Upside: +285.60%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $4.49
Upside: -33.18%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.66
Upside: +4,107.74%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.08
Upside: +198.67%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $59.80
Upside: +50.50%